cost to sale of biological assets. Financial Cost Financial cost in Quarter 2/2019 was Baht 8.5 Million decreased by Baht 1.3 Million or 13.1% from Q2/2018 mainly from bank loan repayment in 2018. Net
Transaction In Quarter 2/2018, the company recorded Baht 22.2 million from gain on sales of deposits for land, Baht 3.9 million from gain on changes in fair value less costs to sell biological asset and Baht
and internal control of subsidiaries improvement. Other Transaction In Quarter 3/2018, the company recorded Baht 4.0 million from gain on changes in fair value less costs to sell biological asset and
essential for economic development and sustainability. Applying science to Thailand?s resource abundance and biological diversity will bring about better quality of life and economic sustainable development
(THB) 0.43 0.25 0.85 +0.19 (0.42) Core EBITDA/T ($) 94 92 115 2% (18)% Operating Cash Flow5 300 340 385 (12)% (22)% Net Operating Debt to Equity (times) 1.32 1.35 0.65 (2)bps +67bps * Integrated Oxides
-Bearing Debt. Our Net Interest-Bearing Debt to Equity ratio was at 0.57x. PERFORMANCE BY BUSINESS Utilities Business Revenue from Sales and Services from Utilities Business in 1Q2018 of Baht 422.0 million
Are Not Debt Instruments or Investment Units dated 3 August 2009; (3) The Notification of the Capital Market Supervisory Board No. Tor Thor. 1/2553 Re: Rules, Conditions and Procedures for Brokerage and
) which increased to 144.5 million baht. 2. Income from debt collection services and other income was 97.1million Baht or increase from the same period last year of 7.9 %. 3. Insurance income in the first
or 3% from last year. The revenues growth came from an increase in credit card income and bad debt recovery. As of May 31, 2017, The Company has active billings of 3.42 million accounts per month with
reference. Notification of the Capital Market Supervisory Board No. TorThor. 63/2552 Re: Rules, Conditions and Procedures for Brokerage and Dealing of Securities Which Are Not Debt Instruments or Investment